Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 34 for:    Han weidong

Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas (CIK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01828008
Recruitment Status : Unknown
Verified January 2013 by Han weidong, Chinese PLA General Hospital.
Recruitment status was:  Not yet recruiting
First Posted : April 10, 2013
Last Update Posted : April 10, 2013
Sponsor:
Information provided by (Responsible Party):
Han weidong, Chinese PLA General Hospital

Tracking Information
First Submitted Date April 6, 2013
First Posted Date April 10, 2013
Last Update Posted Date April 10, 2013
Study Start Date April 2013
Estimated Primary Completion Date May 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 9, 2013)
disease free survival [ Time Frame: 5 years ]
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
Official Title Not Provided
Brief Summary To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Detailed Description Autologous CIK transfusion within 3 days post CD20 antibody treatment.
Study Type Observational [Patient Registry]
Study Design Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration 5 Years
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population the patients with CD20-positive Lymphomas
Condition Lymphomas
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: April 9, 2013)
20
Original Estimated Enrollment Same as current
Estimated Study Completion Date May 2015
Estimated Primary Completion Date May 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy

Exclusion Criteria:

- to refuse the therapy and need not tolerate the therapy

Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01828008
Other Study ID Numbers BT-004
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Han weidong, Chinese PLA General Hospital
Study Sponsor Han weidong
Collaborators Not Provided
Investigators Not Provided
PRS Account Chinese PLA General Hospital
Verification Date January 2013